Anti- HMHA1 Antibody | FNab03935

Anti- HMHA1 Antibody | FNab03935 | Gentaur UK, US & Europe Distribution

Form: liquid

Purification: Immunogen affinity purified

Purity: ≥95% as determined by SDS-PAGE

Host: Rabbit

Clonality: polyclonal

Clone ID: N/A

Isotype: IgG

Storage: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)

Background: GTPase activator for the Rho-type GTPases. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

Immunogen: histocompatibility (minor) HA-1

synonyms: KIAA0223

Molecular weight (observed) : 140-150kd

Reactivity Species: Human, Mouse, Rat

Tested Application: ELISA, WB

Recomended Dillution : WB: 1:500-1:2000; IHC: 1:20-1:200

Research Area: Signal Transduction